loading
前日終値:
$4.90
開ける:
$4.91
24時間の取引高:
190.91K
Relative Volume:
0.32
時価総額:
$284.92M
収益:
$192.64M
当期純損益:
$2.51M
株価収益率:
18.09
EPS:
0.27
ネットキャッシュフロー:
$12.42M
1週間 パフォーマンス:
-4.41%
1か月 パフォーマンス:
+3.07%
6か月 パフォーマンス:
-4.60%
1年 パフォーマンス:
+41.30%
1日の値動き範囲:
Value
$4.83
$4.935
1週間の範囲:
Value
$4.82
$5.12
52週間の値動き範囲:
Value
$3.44
$6.75

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name
名前
Vanda Pharmaceuticals Inc
Name
セクター
Healthcare (1195)
Name
電話
202-734-3400
Name
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
Name
職員
203
Name
Twitter
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
VNDA's Discussions on Twitter

VNDA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
VNDA 4.88 284.92M 192.64M 2.51M 12.42M 0.27
VRTX 449.14 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.22 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 587.39 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.00 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.00 24.89B 3.30B -501.07M 1.03B 11.54

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-07-11 開始されました Cantor Fitzgerald Overweight
2022-02-25 ダウングレード Jefferies Buy → Hold
2021-05-12 開始されました BofA Securities Buy
2021-01-14 ダウングレード Citigroup Buy → Neutral
2020-10-29 アップグレード Citigroup Neutral → Buy
2020-06-09 ダウングレード Citigroup Buy → Neutral
2020-03-16 ダウングレード Oppenheimer Perform → Underperform
2020-03-12 アップグレード Citigroup Neutral → Buy
2019-11-07 ダウングレード Citigroup Buy → Neutral
2019-08-01 アップグレード Citigroup Neutral → Buy
2019-07-25 ダウングレード Stifel Buy → Hold
2018-12-11 ダウングレード Oppenheimer Outperform → Perform
2018-12-04 アップグレード Cantor Fitzgerald Neutral → Overweight
2018-12-04 繰り返されました Jefferies Buy
2018-11-08 再開されました Jefferies Buy
2018-09-21 再開されました Oppenheimer Outperform
2018-05-23 開始されました Citigroup Buy
2018-01-19 開始されました Seaport Global Securities Buy
2017-09-14 繰り返されました Piper Jaffray Overweight
2017-06-27 再開されました Piper Jaffray Overweight
2017-05-26 開始されました H.C. Wainwright Buy
2017-04-12 開始されました Oppenheimer Outperform
2016-11-09 開始されました Aegis Capital Buy
2016-10-06 再開されました Jefferies Buy
すべてを表示

Vanda Pharmaceuticals Inc (VNDA) 最新ニュース

pulisher
Nov 19, 2024

Long Term Trading Analysis for (VNDA) - Stock Traders Daily

Nov 19, 2024
pulisher
Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India

Nov 18, 2024
pulisher
Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 17, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Nov 17, 2024
pulisher
Nov 14, 2024

New Strong Buy Stocks For November 14th - Barchart

Nov 14, 2024
pulisher
Nov 13, 2024

Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Nigeria

Nov 13, 2024
pulisher
Nov 12, 2024

Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Nov 12, 2024
pulisher
Nov 09, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India

Nov 08, 2024
pulisher
Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024
pulisher
Nov 07, 2024

Vanda Pharmaceuticals Inc (VNDA) Quarterly 10-Q Report - Quartz

Nov 07, 2024
pulisher
Nov 07, 2024

Vanda Seeks New Markets for Hetlioz Amid Generic Competition - Sleep Review

Nov 07, 2024
pulisher
Nov 07, 2024

Vanda: Q3 Earnings Snapshot - Middletown Press

Nov 07, 2024
pulisher
Nov 07, 2024

Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... - Yahoo Finance

Nov 07, 2024
pulisher
Nov 06, 2024

Vanda Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results - PR Newswire

Nov 06, 2024
pulisher
Nov 05, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve

Nov 05, 2024
pulisher
Nov 05, 2024

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St

Nov 05, 2024
pulisher
Nov 04, 2024

Analysts Set Expectations for VNDA Q3 Earnings - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan

Oct 30, 2024
pulisher
Oct 28, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat

Oct 28, 2024
pulisher
Oct 24, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN

Oct 22, 2024
pulisher
Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024
pulisher
Oct 19, 2024

Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN

Oct 19, 2024
pulisher
Oct 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire

Oct 17, 2024
pulisher
Oct 15, 2024

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace

Oct 15, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch

Oct 14, 2024
pulisher
Oct 14, 2024

Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com

Oct 14, 2024

Vanda Pharmaceuticals Inc (VNDA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):